Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 Dec 14;60(3):1459-63.
doi: 10.1128/AAC.02610-15.

Does Critical Illness Change Levofloxacin Pharmacokinetics?

Affiliations
Observational Study

Does Critical Illness Change Levofloxacin Pharmacokinetics?

Jason A Roberts et al. Antimicrob Agents Chemother. .

Abstract

Levofloxacin is commonly used in critically ill patients for which existing data suggest nonstandard dosing regimens should be used. The objective of this study was to compare the population pharmacokinetics of levofloxacin in critically ill and in non-critically ill patients. Adult patients with a clinical indication for levofloxacin were eligible for participation in this prospective pharmacokinetic study. Patients were given 500 mg or 750 mg daily by intravenous administration with up to 11 blood samples taken on day 1 or 2 of therapy. Plasma samples were analyzed and population pharmacokinetic analysis was undertaken using Pmetrics. Thirty-five patients (18 critically ill) were included. The mean (standard deviation [SD]) age, weight, and Cockcroft-Gault creatinine clearance for the critically ill and for the non-critically ill patients were 60.3 (16.4) and 72.0 (11.6) years, 78.5 (14.8) and 70.9 (15.8) kg, and 71.9 (65.8) and 68.2 (30.1) ml/min, respectively. A two-compartment linear model best described the data. Increasing creatinine clearance was the only covariate associated with increasing drug clearance. The presence of critical illness did not significantly affect any pharmacokinetic parameter. The mean (SD) parameter estimates were as follows: clearance, 8.66 (3.85) liters/h; volume of the central compartment (Vc), 41.5 (24.5) liters; intercompartmental clearance constants from central to peripheral, 2.58 (3.51) liters/h; and peripheral to central compartments, 0.90 (0.58) liters/h. Monte Carlo dosing simulations demonstrated that achievement of therapeutic exposures was dependent on renal function, pathogen, and MIC. Critical illness appears to have no independent effect on levofloxacin pharmacokinetics that cannot be explained by altered renal function.

PubMed Disclaimer

Figures

FIG 1
FIG 1
(a) Diagnostic plots for the final covariate model. Observed versus population predicted concentrations (left) and individual predicted concentrations (right) in plasma are shown. (b) Visual predictive check for the final covariate model where the y axis output is levofloxacin concentration. Data are presented in milligrams per liter.
FIG 2
FIG 2
Monte Carlo simulations and the probability of target attainment in plasma for various levofloxacin doses for creatinine clearances of 30 ml/min, 70 ml/min,130 ml/min, and 200 ml/min.

References

    1. Fish DN, Chow AT. 1997. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 32:101–119. doi:10.2165/00003088-199732020-00002. - DOI - PubMed
    1. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125–129. doi:10.1001/jama.279.2.125. - DOI - PubMed
    1. Boselli E, Breilh D, Rimmele T, Djabarouti S, Saux MC, Chassard D, Allaouchiche B. 2005. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med 33:104–109. doi:10.1097/01.CCM.0000150265.42067.4C. - DOI - PubMed
    1. Furlanut M, Brollo L, Lugatti E, Di Qual E, Dolcet F, Talmassons G, Pea F. 2003. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 51:101–106. doi:10.1093/jac/dkg035. - DOI - PubMed
    1. Rebuck JA, Fish DN, Abraham E. 2002. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 22:1216–1225. doi:10.1592/phco.22.15.1216.33484. - DOI - PubMed

Publication types

MeSH terms